Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis
Top Cited Papers
Open Access
- 1 December 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 39 (12) , 3297-3302
- https://doi.org/10.1161/strokeaha.108.516450
Abstract
Background and Purpose— The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found that treatment with atorvastatin 80 mg per day reduced the risk of stroke and cardiovascular events in patients with a recent transient ischemic attack (TIA) or stroke. We hypothesized this benefit would be greatest in the subgroup of patients with carotid stenosis.Keywords
This publication has 10 references indexed in Scilit:
- Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic AttackStroke, 2007
- Autopsy Prevalence of Coronary Atherosclerosis in Patients With Fatal StrokeStroke, 2007
- High-Dose Atorvastatin after Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2006
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trialThe Lancet, 2004
- Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) StudyCerebrovascular Diseases, 2003
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Identifying patient populations at high risk for strokeNeurology, 1998
- Endarterectomy for Asymptomatic Carotid Artery StenosisJAMA, 1995
- NATURAL HISTORY OF ASYMPTOMATIC EXTRACRANIAL ARTERIAL DISEASEBrain, 1987